CN1293065C - 作为类固醇硫酸酯酶抑制剂的哌嗪基-或哌啶基胺─氨基磺酸酰胺 - Google Patents
作为类固醇硫酸酯酶抑制剂的哌嗪基-或哌啶基胺─氨基磺酸酰胺 Download PDFInfo
- Publication number
- CN1293065C CN1293065C CNB038083361A CN03808336A CN1293065C CN 1293065 C CN1293065 C CN 1293065C CN B038083361 A CNB038083361 A CN B038083361A CN 03808336 A CN03808336 A CN 03808336A CN 1293065 C CN1293065 C CN 1293065C
- Authority
- CN
- China
- Prior art keywords
- compound
- trifluoromethyl
- formula
- aminocarboxyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JUTQLSRBKSVCLI-UHFFFAOYSA-N piperidin-1-amine;sulfamide Chemical class NS(N)(=O)=O.NN1CCCCC1 JUTQLSRBKSVCLI-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title description 17
- 108010087999 Steryl-Sulfatase Proteins 0.000 title 1
- 102100038021 Steryl-sulfatase Human genes 0.000 title 1
- 102000005262 Sulfatase Human genes 0.000 claims abstract description 28
- 108060007951 sulfatase Proteins 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 122
- -1 aminocarboxyl Chemical group 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical group 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 10
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000005936 piperidyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 238000000034 method Methods 0.000 description 22
- 239000003163 gonadal steroid hormone Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 19
- 208000002874 Acne Vulgaris Diseases 0.000 description 15
- 206010000496 acne Diseases 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 201000004384 Alopecia Diseases 0.000 description 9
- 206010020112 Hirsutism Diseases 0.000 description 9
- 231100000360 alopecia Toxicity 0.000 description 9
- 238000013016 damping Methods 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000001076 estrogenic effect Effects 0.000 description 6
- 229960003399 estrone Drugs 0.000 description 6
- 208000008742 seborrheic dermatitis Diseases 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 101000661600 Homo sapiens Steryl-sulfatase Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 241000220645 Leonotis nepetifolia Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 201000003914 endometrial carcinoma Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003270 steroid hormone Substances 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000935 solvent evaporation Methods 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000006477 desulfuration reaction Methods 0.000 description 2
- 230000023556 desulfurization Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 1
- MXIUWSYTQJLIKE-UHFFFAOYSA-N 2-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1C(Cl)=O MXIUWSYTQJLIKE-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- BQNZIRSNAKWERJ-UHFFFAOYSA-N 2-fluoro-4-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=C(C(F)(F)F)C=C1F BQNZIRSNAKWERJ-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MQTOSJVFKKJCRP-HHZDEWPHSA-N Azythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@H]([C@@]([C@H](O)[C@H](C)N(C)C[C@@H](C)C[C@](C)(O)[C@@H](O[C@@H]2[C@H]([C@@H](C[C@H](C)O2)N(C)C)O)[C@@H]1C)(C)O)CC)[C@@H]1C[C@](C)(OC)[C@H](O)[C@@H](C)O1 MQTOSJVFKKJCRP-HHZDEWPHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本发明涉及哌嗪基-或哌啶基胺-氨基磺酸酰胺以及它们用于制备治疗类固醇硫酸酯酶介导的疾病的药物中的用途。
Description
本发明涉及氨基磺酸酰胺,这些化合物可以用于治疗例如由类固醇硫酸酯酶活性所介导的紊乱。
一方面,本发明提供式I的化合物:
其中
-R1和R2与它们相连的氮原子一起为哌嗪基,其中第二个氮原子由(C1-6)烷氧羰基或由(C6-18)芳基取代,其中(C6-18)芳基可由一个或多个卤素、(C1-6)卤代烷基(如CF3)、氨基羰基取代;
或者
-R1为氢而R2为哌啶基,经哌啶环上的碳原子相连,其中氮原子由(C1-6)烷氧羰基或由(C6-18)芳基取代,并且
R3为(C6-18)芳基或(C6-18)芳基(C1-4)烷基,其中芳基可由一个或多个卤素、氨基羰基或(C1-6)卤代烷基取代。
如果没有另外指明,此处的(C6-18)芳基(如苯基),为由一个或多个卤素、(C1-6)卤代烷基(如CF3)或氨基羰基取代的(C6-18)芳基。
(C1-6)烷氧羰基包括未取代的或取代的(C1-6)烷氧羰基,如烷基由(C6-18)芳基(如苯基)取代的烷氧羰基(如苄氧基羰基)。卤素包括氟、氯、溴、碘,如氟、氯。(C6-18)芳基(C1-4)烷基优选为苯基(C1-4)烷基(如苯乙基),其中苯基的取代基与所述(C6-18)芳基取代基相同。
优选的式I化合物定义如下:
-R1和R2与氮原子一起为哌嗪基,其中第二个氮原子由
-(C1-6)烷氧羰基(如叔丁氧基羰基、苄氧基羰基)取代,
-由氨基羰基、(C1-6)卤代烷基取代的苯基取代,或者
-R1为氢而R2为哌啶基,经哌啶环上的碳原子相连,其中氮原子由
-(C1-6)烷氧羰基(如叔丁氧基羰基、苄氧基羰基)取代,
-由氨基羰基、(C1-6)卤代烷基取代的苯基取代,且
-R3为
由一个或多个选自下列的基团取代的苯基:
-卤素,
-(C1-6)卤代烷基(如CF3),
-氨基羰基,
或者为
苯基取代的(C1-4)烷基,其中苯基由一个或多个选自下列的基团取代:
-卤素,
-(C1-6)卤代烷基(如CF3),
-氨基羰基。
另一方面,本发明提供选自下式化合物组的式I化合物:
其中
a.R3ss为3,5-二(三氟甲基)苯基而R4ss为2-氨基羰基-5-三氟甲基苯基,
b.R3ss为2,3-二氯苯基,R4ss为2-氨基羰基-5-三氟甲基苯基,
c.R3ss为3,5-二氯苯基,R4ss为2-氨基羰基-5-三氟甲基苯基,以及
d.R3ss为3,5-二(三氟甲基)苯基而R4ss为叔丁氧基羰基;
优选的R3ss为3,5-二(三氟甲基)苯基。
另一方面,本发明提供选自下式化合物组的式I化合物
其中
a.R3s为3,5-二(三氟甲基)苯基而R4s为叔丁氧基羰基,
b.R3s为2,3-二氯苯基而R4s为叔丁氧基羰基,
c.R3s为3,5-二氯苯基而R4s为叔丁氧基羰基,
d.R3s为3,5-二(三氟甲基)苯基而R4s为苄氧基羰基,
e.R3s为2,3-二氯苯基而R4s为苄氧基羰基,
f.R3s为3,5-二氯苯基而R4s为苄氧基羰基,
g.R3s为3,5-二氯苯基而R4s为苄氧基羰基,
h.R3s为3,5-二(三氟甲基)苯基而R4s为2-氨基羰基-5-三氟甲基苯基,
i.R3s为3,5-二氯苯基而R4s为2-氨基羰基-5-三氟甲基苯基,
j.R3s为2,3-二氯苯基而R4s为2-氨基羰基-5-三氟甲基苯基,以及
k.R3s为2-(3,5-二(三氟甲基)苯基)乙基而R4s为叔丁氧基羰基。
本发明所提供的化合物在下文中被称为“本发明化合物”。式I化合物包括式Is化合物和式Iss化合物。在本发明化合物中上述的每个取代基本身都可以是一个优选的取代基,而与其他所述的取代基无关。本发明化合物包括任何形式的化合物,如游离形式、盐形式、溶剂化物形式以及盐的溶剂化物形式。
另一方面,本发明提供盐形式的本发明化合物。
虽然优选的盐为药学上可接受的盐,但是在制备、分离、纯化过程中仍可采用药学上不可接受的盐。
本发明化合物的盐包括金属盐、酸加成盐或胺盐。金属盐包括碱金属或碱土金属盐;酸加成盐包括本发明化合物与酸(如HCl)的盐;胺盐包括本发明化合物与胺的盐。盐形式的本发明化合物优选金属盐。
游离形式的本发明化合物可转化为相应盐形式的化合物;反之亦然。游离形式或盐形式及溶剂化物形式的本发明化合物可转化为相应游离形式或盐形式及非溶剂化物形式的化合物;反之亦然。
本发明化合物可以以异构体形式及其混合物存在;如光学异构体、非对应异构体、顺式/反式构象异构体。本发明化合物也可含有例如不对称碳原子,因此也可以以对映异构体或非对映异构体形式及其它们的混合物存在,如外消旋物。不对称碳原子可以(R)-、(S)-或(R,S)-构型存在,优选以(R)-或(S)-构型存在。
根据例如类似于常用方法的方法,分离异构体混合物得到纯的异构体。本发明包括以任何异构体和异构体混合物形式存在的本发明化合物。
本发明也包括式I化合物的互变异构体,如果互变异构体可以存在的话。
根据例如类似于常用方法或本文说明的方法,在适当情况下制备本文所述的化合物,如本发明化合物。
另一方面,本发明提供制备本发明化合物的方法,该方法包含如下步骤且将反应步骤A、B2或反应步骤C6中所获得的式I化合物从反应混合物中分离,
A.以使式II化合物:
其中R1和R2如上所述,与如酰氯的活化形式的式III化合物反应,该反应或者在偶联剂存在的情况下进行,式III如下:
其中R3如上所述;
或者
B1.使其中R1和R2与它们相连的氮原子一起为未取代的哌嗪基的式II化合物与其中R3如上所述的如酰氯的活化形式的式III化合物反应,该反应或者在偶联剂存在的情况下进行,从而得到式IV的化合物:
其中R3如上所述;并且
B2.在碱(K2CO3)存在的情况下,使式IV化合物与任选取代的(C6-18)氟代芳基(如氟代苯基)反应得到式I化合物,其中所述任选取代的芳基的取代基如式I化合物所定义的,在得到的式I化合物中,R1和R2与它们相连的氮原子一起为哌嗪基,其在第二个氮原子上由任选取代的(C6-18)芳基取代;或者
C1.在NaBH4存在的情况下,使式V化合物与苯甲醛反应,式V化合物如下:
其中RSUB为(C1-6)烷氧羰基,得到式VI化合物:
其中RSUB如上所定义且Bnz为苄基,
C2.使式VI化合物与H2N-SO2-NH2反应得到式VII化合物:
其中RSUB和Bnz如上所定义,
C3.使式VII化合物与其中R3如上所定义的R3-COOH反应得到式VIII化合物,在R3-COOH中,羧基为活化形式,式VIII化合物如下:
其中RSUB、Bnz和R3如上所定义,
C4.使式VIII化合物与醚化HCl反应,得到式IX化合物,
其中Bnz和R3如上所定义,
C5.在碱(如K2CO3)存在的情况下,使式IX化合物与任选取代的(C6-18)氟代芳基(如氟代苯基)反应,得到式X化合物,其中上述任选取代的芳基的取代基如式I化合物所定义的,式X化合物为其中Bnz和R3如上所定义且哌啶基的氮原子由任选取代的(C6-18)芳基取代的式IX化合物,
C6.在钯催化剂存在的情况下,将步骤C5中得到的化合物氢化,得到式I化合物,其中R1为H,R2为由任选取代的(C6-18)芳基取代的哌啶,且R3如上所定义。
在式I化合物的制备中,式II、III、IV、V、VI、VII、VIII、IX和X化合物为中间体(原料)。如果这些中间体(原料)中存在官能团,那么这些官能团可以任选为保护形式或者盐形式(如果有形成盐的基团存在)。根据例如与常用方法类似的方法,在适当阶段将任选存在的保护基团去除。因此,获得的式I化合物可以转化为其他式I化合物或者获得的游离形式的式I化合物可以转化为盐形式的式I化合物,反之亦然。
根据例如类似于常用方法或本文说明的方法,在例如适当溶剂和温度下进行上述反应。中间体(原料)是已知的或者可以根据常用方法或本文说明的方法在适当情况下获得。根据例如类似于常用方法或本文说明的方法,在适当情况下可以制备本文所述的化合物,如本发明化合物。
在特定组织中的类固醇激素与多种疾病有关,如乳腺癌、子宫内膜癌和前列腺癌以及毛囊皮脂腺紊乱(如痤疮、男性秃头症和多毛症)。产生这些局部类固醇激素重要前体为类固醇3-O-硫酸酯,由靶组织内的类固醇硫酸酯酶脱硫酸产生。抑制这种酶可使相关活性的类固醇激素局部水平下降,当然也具有治疗上的价值。而且,类固醇硫酸酯酶抑制剂也可用作免疫抑制剂,并且当被递送到脑内时具有增强记忆的功能。
痤疮是由多种因素(如遗传、皮脂、激素和细菌)相互作用的多病因疾病。在痤疮中,最重要的致病因素是皮脂的产生;与健康皮肤的人群相比,几乎所有痤疮患者的皮脂腺都更大且能产生更多的皮脂。雄激素控制皮脂腺的发育及皮脂产生的程度;因此,雄激素在痤疮的发病机理中具有重要作用。在男性中,目标组织中的雄激素有两个主要的来源:(i)分泌睾酮的性腺,(ii)产生脱氢表雄甾酮(DHEA)的肾上腺,脱氢表雄甾酮是以硫酸酯共轭物的形式分泌的。在目标组织(如皮肤)中,睾酮和DHEAS都可以转化为最具有活性的雄激素双氢睾酮(DHT)。证据表明,这种在皮肤内局部合成DHT的途径与血液循环直接提供活性雄激素相比更重要。因此,用特定抑制剂减少目标组织中内源性雄激素的水平在痤疮和脂溢性皮炎的治疗中有重要意义。而且,这开辟了局部治疗该种紊乱的前景,只需调节局部雄激素水平而不需通过系统治疗影响循环系统内的激素水平。
在白种人中,雄激素所致的男性秃头症非常普遍,约占各种类型的秃头症的95%。毛发生长终期的头皮毛囊数量增加以及毛发生长终期持续的时间长导致了男性秃头。雄激素影响的头发脱落是由遗传决定。在男性秃头和非秃头的对照中,血浆DHEA升高而睾酮水平正常,这意味着在雄激素所致的秃头中靶组织产生雄激素起重要作用。
多毛症是毛发病理性的增粗变硬,其特征为在儿童和妇女中毛发的生长类似男性。多毛症是由雄激素引起的,由于雄激素产生的增加或者毛囊对雄激素的敏感性增加。因此,在痤疮、男性秃头症和多毛症的治疗中降低靶组织(皮肤)中内源性雄激素和/或雌激素的水平是有效的。
如上所述,全身大量的前体DHEAS在皮肤内合成了最具活性的雄激素DHT,从DHEAS到DHT的代谢途径的第一步为经类固醇硫酸酯酶催化进行的脱硫酸反应,该反应产生DHEA。已知在角化细胞和源自皮肤的纤维原细胞中存在上述酶。采用已知的类固醇硫酸酯酶抑制剂(如雌酮3-O-氨基磺酸酯和4-甲基伞形基-7-O-氨基磺酸酯)能够证实类固醇硫酸酯酶抑制剂在降低皮肤中内源性类固醇激素水平的可能用途。申请人发现胎盘类固醇硫酸酯酶抑制剂还可抑制人角质细胞(HaCaT)和源自人皮肤的纤维原细胞系(1BR3GN)产生类固醇硫酸酯酶。这些抑制剂同样也抑制HaCaT角质细胞整个单细胞层中的类固醇硫酸酯酶。
因此,类固醇硫酸酯酶抑制剂可降低皮肤内雄激素和雌激素水平。可作为类固醇硫酸酯酶抑制剂用于雄激素依赖性的毛囊皮脂腺紊乱(如痤疮、脂溢性皮炎、男性秃头症、多毛症)和鳞状上皮细胞癌的局部治疗。
此外,非甾族的类固醇硫酸酯酶抑制剂被认为可用于治疗由类固醇激素介导的紊乱,其中起作用的是硫酸酯酶裂解类固醇产物。这些新型抑制剂的适应症包括雄激素依赖型毛囊皮脂腺紊乱(如痤疮、脂溢性皮炎、男性秃头症、多毛症);雌激素或雄激素依赖型肿瘤如鳞状上皮细胞癌及瘤,如乳腺癌、子宫内膜癌和前列腺癌;感染和自身免疫性疾病如风湿性关节炎、I型和II型糖尿病、系统性红斑狼疮、多发性硬化、重症肌无力、甲状腺炎、脉管炎、溃疡性结肠炎及局限性回肠炎、牛皮癣、接触性皮炎、移植排斥反应、湿疹、哮喘和器官移植排斥。类固醇硫酸酯酶抑制剂也用于癌症的治疗,尤其用于雌激素/雄激素依赖型癌症的治疗,如乳腺癌和子宫内膜癌及鳞状上皮细胞癌和前列腺癌。通过增加中枢神经系统的DHEAS水平,类固醇硫酸酯酶抑制剂也用于增加认知功能,尤其用于治疗老年性痴呆(包括阿尔茨海默病)。
在如下的一系列试验中将证明化合物对类固醇硫酸酯酶的抑制作用:人类固醇硫酸酯酶的纯化
将分娩后得到的新鲜人胎盘剥去膜和结缔组织。冷冻保存在-70℃。融化后,在4℃下进行如下步骤,当20℃时调节pH值。在1.2升的缓冲液A(50mM Tris-HCl,pH 7.4,0.25M蔗糖)中将400g的组织均化。将所得到的组织均浆在10,000xg下离心45分钟。留出上清液并将所得到的沉淀物在500ml缓冲液A中再次均化。离心后,将两次得到的上清液混合并超速离心(100,000xg,1小时)。将得到的沉淀物再次悬浮于缓冲液A中并再次离心。所得的沉淀物悬浮于50ml的50mM Tris-HCl中,pH 7.4并贮存在-20℃直到进行下一步。
融化后,通过超速离心(如上所述)收集微粒体并悬浮于50ml缓冲液B(10mM Tris-HCl,pH 7.0,1mM EDTA,2mM 2-巯基乙醇,1% TritonX-100,0.1%抑肽酶)中。放置于冰上并轻轻搅拌1小时后,离心混悬液(100,000xg,1小时)。收集含有酶活性的上清液并用1M Tris将pH值调节到8.0。将所得到的溶液经羟基磷灰石柱层析(2.6×20cm)并用缓冲液B(pH8.0)平衡。在流速2ml/min下用缓冲液B冲洗柱。回收含有活性组分的流分。将收集池的pH值调节到7.4,再经缓冲液C(20mM Tris-HCl,pH 7.4,0.1% Triton X-100,0.5M NaCl)平衡的伴刀豆球蛋白A琼脂糖凝胶柱层析(1.6×10cm)。用缓冲液C冲洗柱,并用溶于缓冲液C的10%甲基甘露糖苷洗脱结合蛋白。时间活性部分并对缓冲液D(20mM Tris-HCl,pH 8.0,1mM EDTA,0.1% Triton X-100,10%甘油(v/v))透析。
将得到的保留物经缓冲液D平衡的蓝色琼脂糖凝胶柱层析(0.8×10cm);洗涤柱并采用线性梯度(缓冲液D至溶于缓冲液D的2M NaCl)洗脱。神经活性部分,需要时进行浓缩(Centricon 10),对缓冲液D透析,分等分在-20℃贮存。
人类固醇硫酸酯酶试验
已知纯化的人类固醇硫酸酯酶不仅能够裂解类固醇硫酸酯,而且能够容易地裂解芳基硫酸酯(如在本试验系列中作为活性指示剂的4-甲基伞形基硫酸酯)。在白色微量滴定板的孔内连续加入下述溶液来制备试验混合物:
1)50μl酶作用物溶液(溶于0.1M Tris-HCl的1.5mM 4-甲基伞形基硫酸酯,pH 7.5)
2)50μl溶于0.1M Tris-HCl(pH 7.5,0.1% Triton X-100)的试验化合物稀释液在DMSO中制备试验化合物的储液;试验混合物中溶剂的终浓度不超过1%)
3)50μl酶稀释液(约12单位酶/ml)
申请人将1单位酶定义为在37℃下溶于0.1M Tris-HCl,pH 7.5,0.1%Triton X-100中的酶作用物的初始浓度为500μM的条件下,每小时可水解1nmol 4-甲基伞形基硫酸酯的类固醇硫酸酯酶的量。
在37℃下孵育滴定板1个小时。然后加入100μl 0.2M NaOH停止反应。用λex=355nm和λem=460nm的Titertek Fluoroskan II装置测定荧光强度。
相对IC50值的计算
根据在上述人类固醇硫酸酯酶试验中获得的不同浓度试验化合物的荧光强度数据(I),用如下方程式计算抑制酶活性50%(IC50)的化合物的浓度:
其中I100为无抑制剂情况下所得的强度,s为斜率。氨基磺酸雌酮作为参照化合物,它的IC50值测定类似于其他所有试验化合物。相对IC50值的定义如下:
根据对上述试验结果的计算,氨基磺酸雌酮的IC50值约为60nM。
在上述试验中,证明本发明化合物具有活性,相对IC50的范围为0.0046-350。
CHO/STS试验
将用人类固醇硫酸酯酶稳定转染的CHO细胞(CHO/STS)接种在微量滴定板上。达到约90%汇合后,将它们与一系列浓度的试验物(如本发明化合物)一起培养过夜。然后在室温下用4%低聚甲醛固定10分钟并用PBS冲洗4次,之后与溶于0.1M Tris-HCl(pH 7.5)中的0.5mM 4-甲基伞形基硫酸酯(MUS)(100μl/孔)共同培养。在37℃下进行酶反应30分钟。然后加入50μl/孔的中止溶液(1M Tris-HCl,pH 10.4)。将酶反应溶液转入白色培养板(Microfluor,Dynex,Chantilly,VA)上并在Fluoroskan II荧光微量滴定板读板仪上进行读板。从所有值中扣除试剂空白值。在药物试验中,用sulforhodamine B(OD550)将细胞蛋白染色后,为了校正细胞数量的偏差,荧光单位(FU)需除以光密度读数。通过两个点(two bracketing points)间的线性内插法测定IC50值。在具有抑制剂的每个试验中,将雌酮3-O-氨基磺酸酯作为参照化合物,IC50值以雌酮3-O-氨基磺酸酯为标准(相对IC50=化合物IC50/雌酮3-O-氨基磺酸酯IC50)。
在上述试验中,本发明化合物显示出活性(相对IC50的范围为0.05-226)。
人皮肤组织均浆试验
将冷冻的人尸体皮肤样品(每份样品约100mg)用锋利剪刀剪成小片状(约1×1mm)。将所剪的碎片悬浮于10体积(w/w)的含有0.1% TritonX-100的缓冲液(20mM Tris-HCl,pH 7.5)中。将取自溶于乙醇或DMSO中储液的试验化合物(如本发明化合物)按照一系列的浓度加入。第二步,将DHEAS作为酶作用物加入(1μC/ml[3H]DHEAS,比活性:约60Ci/mmol,和20μM未标记的DHEAS)。在37℃下将样品培养18个小时。培养结束后加入50μl的1M Tris(pH 10.4)和3ml的甲苯。每等份有机相取出1ml并进行液体闪烁计数。将测定的每等份中的dpm值转化为每小时裂解的每克皮肤中的DHEA的nmol值。
本发明化合物在上述试验中显示出活性(IC50的范围为0.03-10μM)。
优选的本发明化合物包括实施例1的化合物。该化合物在人类固醇硫酸酯酶试验中相对IC50的范围为0.0046-0.071,在CHO/STS试验中相对IC50的范围为0.02-0.39,以及在人皮肤组织均浆试验中的IC50的范围为0.03-0.27μM,因此该化合物为高活性的类固醇硫酸酯酶抑制剂。
在上述系列试验中证明了本发明化合物的活性。盐和/或溶剂化物形式的本发明化合物与游离和/或非溶剂化物形式的本发明化合物显示出相当的活性。
因此,本发明化合物可用作类固醇硫酸酯酶抑制剂,用于治疗类固醇硫酸酯酶介导的紊乱,例如包括雄激素依赖型的毛囊皮脂腺紊乱,如
-痤疮,
-脂溢性皮炎,
-男性秃头症,
-多毛症;
-癌症,如雌激素和雄激素依赖型的癌症;
-认知功能紊乱,如包括阿尔茨海默氏病的老年性痴呆。
本发明化合物优选用于痤疮、脂溢性皮炎、男性秃头症、多毛症的治疗;雌激素和雄激素依赖型癌症,更优选用于痤疮的治疗。治疗包括治疗学的治疗和预防。
另一方面,本发明也提供本发明化合物在药物(如药物组合物)制备中的用途,所说的药物用于治疗类固醇硫酸酯酶介导的紊乱,如对类固醇硫酸酯酶的抑制作用有响应的紊乱,更优选痤疮。
在上述用途中,本发明化合物可包括一种或多种本发明化合物,如两种或多种本发明化合物的联合,优选一种化合物。
另一方面,本发明提供用作药物的本发明化合物。
另一方面,本发明提供类固醇硫酸酯酶介导的紊乱的治疗方法,所述紊乱包括痤疮、脂溢性皮炎、男性秃头症、多毛症;癌症,如雌激素和雄激素依赖型的癌症;认知功能紊乱,如包括阿尔茨海默病的老年性痴呆,优选痤疮,所述治疗方法包括给予需要所述治疗的患者治疗有效量的本发明化合物(如以药物组合物的形式)。
所述治疗包括治疗和预防。
在上述治疗中,适当的剂量当然应根据例如所用本发明化合物的化学性质及药物动力学、个体、给药方式和所治疗的疾病的性质和严重程度的不同而不同。然而,在通常情况下,如果每天每公斤动物体重给药约0.1mg-约100mg就可以达到满意的疗效,如每天分两至四次给药。对于大多数哺乳动物来说,每天的总剂量为约5mg-约5000mg,每天给药最多可分为四次或者采用缓释形式。单位剂量形式包括本发明化合物(约1.25mg-约2000mg)与至少一种药学上可接受的赋形剂(如载体、稀释剂)。
本发明化合物的给药可通过任意常用途径进行,如肠内给药,包括鼻内、颊部、直肠、经口给药;肠胃外给药,例如包括静脉、肌肉、皮下给药;或者局部给药,包括表皮(epicutaneous)、鼻内、气管内给药;可以为有包衣或无包衣的片剂、胶囊、安瓿或小瓶形式的注射溶液或者混悬液,可以为膏剂、霜剂、凝胶剂、糊剂、吸入剂、粉剂、泡沫剂、酊剂、唇膏、滴剂、喷雾剂或者栓剂。本发明化合物可以以药学上可接受的盐形式或者游离形式给药;任选溶剂化物形式。盐形式的本发明化合物与游离和任选溶剂化物形式的本发明化合物显示出相同的活性。
根据本发明,本发明化合物可以单独用于治疗,或与一种或多种其他药物活性剂联合。这些其他的药物活性剂包括类视色素,如视磺酸,比如异维A酸、维A酸(Roche)、阿达帕林(6-[3-(1-金刚烷基)-4-甲氧基苯基]-2-萘甲酸);口服避孕药,如19-降-17a-孕-1,3,5(10)-三烯-20-in-3,17-二醇、6-氯-17-羟基-1a,2a-亚甲基-4,6-孕二烯-3,20-二酮,如Diane(Schering);包括红霉素类的抗生素,如红霉素A、阿奇霉素、克拉霉素、罗红霉素;包括四环素、lincosamid-抗生素,如氯洁霉素(甲基7-氯-6,7,8-三脱氧-6-(反式-1-甲基-4-丙基-L-2-吡咯烷基-甲酰氨基)-1-硫-L-苏型-a-D-半乳糖-八吡喃糖苷)、壬二酸(nonanedionic acid),那氟沙星;包括氨苯砜、过氧化苯甲酰;包括角质分离剂,如水杨酸;包括抗炎药物,如皮质类固醇、吡美莫司;包括类固醇5α-还原酶抑制剂。
此外,治疗乳腺癌和子宫内膜癌时,所述药物活性剂还可包括芳香酶抑制剂,如阿那曲唑、来曲唑、依西美坦。
所述联合包括
-固定联合,其中在同一个药物组合物中存在两种或多种药物活性剂,
-药盒,其中两种或多种药物活性剂为单独的组合物,但是被放置于同一个包装内出售,例如还可以包括共同给药的说明;以及
-自由联合,其中药物活性剂各自独立包装,但是提供同时或先后给药的使用说明。
另一方面,本发明提供含有本发明化合物与至少一种药物赋形剂的药物组合物,适当的赋形剂为如载体和/或稀释剂,包括例如填充剂、粘合剂、崩解剂、流动调节剂、润滑剂、甜味剂、香味剂、防腐剂、稳定剂、湿润剂和/或乳化剂、增溶剂、调节渗透压的盐、缓冲剂。
另一方面,根据本发明还提供含有其他药物活性剂的药物组合物。
可根据例如类似于常用方法(如通过混合、制粒、包衣、溶解或冻干方法)的方法,制备这些药物组合物。
在如下实施例中,所涉及的温度为未校正的摄氏温度。如果没有其他说明,在CDCl3中测定1HNMR。采用如下缩写:
m.p.:熔点
EtAc:乙酸乙酯
BOC:叔丁氧基羰基
DMF:N,N-二甲基甲酰胺
RT:室温
DMSO:二甲亚砜
实施例1
N-[[4-[1-(2-氨基羰基-5-三氟甲基-苯基)[-哌啶基]-氨基]-磺酰基-3,5-二-三氟甲基-苯甲酰胺
A)4-[N-(氨基磺酰基)-苄基氨基]-哌啶-1-甲酸叔丁基酯
将溶于100ml 1,2-二甲氧基-乙烷中的2.05g 4-苄基氨基-哌啶-1-甲酸叔丁基酯和3.39g磺酰胺溶液回流大约10小时。将所获得的混合物的溶剂蒸发,用EtAc处理所得的蒸发残留物,滤除未溶解部分。滤液经硅胶柱层析。得到4-[N-(氨基磺酰基)-苄基氨基]-哌啶-1-甲酸叔丁基酯。mp140-142℃。1H-NMR(DMSO)δ:7.30-7.41(s/m,9+2H),1.64(m,2H),2.53-2.72(宽峰,2H),3.71(tt,1H),8.83-8.96(宽峰,2H),4.26(s,2H,CH2),6.86(bs,2H,NH),7.19(t,1H),7.28(t,1H),7.36(d,1H)。13C-NMR(DMSO)δ:28.51,30.13,43.35,47.11,56.52,79.12,127.06,127.48,128.49,140.59,154.156。
B)N-(1-BOC-4-哌啶基-苄基氨基)-磺酰基-3,5-二-三氟甲基-苯甲酰胺
将280mg二异丙基-乙胺和1.28ml正丙基膦酸酐(50% DMF溶液)加入溶于15ml DMF中的400mg 4-[N-(氨基磺酰基)-苄基氨基]-哌啶-1-甲酸叔丁基酯和560mg 3,5-二-(三氟甲基)安息香酸的溶液内。在室温下搅拌所得的混合物大约4天,蒸发溶剂并将所得的蒸发残留物用EtAc处理,用1N HCl、饱和的NaHCO3溶液和盐水冲洗,然后干燥。将干燥的残留物中的溶剂蒸发并将所得的蒸发残留物经硅胶柱层析。得到N-(1-BOC-4-哌啶基-苄基氨基)-磺酰基-3,5-二-三氟甲基-苯甲酰胺。
1H-NMR(DMSO)δ:1.28-1.40(m,9+2H),1.60(m,2H),2.54-2.70(m,2H),3.80-3.94(m,2+1H),4.55(s,2H,CH2),7.18(t,1H),7.27(d,1H),7.37(d,1H),8.26(s,1H),8.46(s,2H),12.6(宽峰,1H,NH).
C)盐酸盐形式的N-(4-哌啶基-苄基氨基)-磺酰基-3,5-二-三氟甲基-苯甲酰胺
用溶于乙醚的60ml 3N HCl(气体)处理溶于5ml CH2Cl2中的650mgN-(1-BOC-4-哌啶基-苄基氨基)-磺酰基-3,5-二-三氟甲基-苯甲酰胺溶液。所得混合物搅拌大约12小时,溶剂被蒸发。得到盐酸盐形式的N-(4-哌啶基-苄基氨基)-磺酰基-3,5-二-三氟甲基-苯甲酰胺。1H-NMR(DMSO)δ:1.72-1.86(m,4H),2.90(m,2H),3.20-3.3(m,2H),4.15(m,1H),4.60(s,2H,CH2),7.31(t,1H),7.40(t,1H),7.48(d,1H),8.38(s,1H),8.48(s,2H),8.48和8.75(宽峰,2H,NH).
D)N-[[4-[1-(2-氨基羰基-5-三氟甲基-苯基)]-哌啶基]-苄基氨基]-磺酰基-3,5-二-三氟甲基-苯甲酰胺
将430mg 2-氟-4-三氟甲基-苯甲酰胺和430mg K2CO3加入溶于15mlDMSO中的570mg N-(4-哌啶基-苄基氨基)-磺酰基-3,5-二-三氟甲基苯甲酰胺盐酸盐溶液内。在150℃下将所得的化合物搅拌大约4小时并且通过过滤去除K2CO3。将所得滤液的溶剂蒸发并且使蒸发残留物经硅胶柱层析。得到N-[[4-[1-(2-氨基羰基-5-三氟甲基-苯基)]-哌啶基]-苄基氨基]-磺酰基-3,5-二-三氟甲基-苯甲酰胺。1H-NMR(DMSO)δ:1.60-1.76(m,4H),2.72(m,2H),3.13(m,2H),3.78(m,1H),4.55(s,2H,CH2),7.14(t,1H),7.23(t,1H),7.26(d,1H),7.32(d,1H),7.41(d,1H),7.59(宽峰,1H,NH),7.68(d,1H),8.08(宽峰,1H,NH),8.12(s,1H),8.45(s,2H).
E)N-[[4-[1-(2-氨基羰基-5-三氟甲基-苯基)]-哌啶基]-氨基]-磺酰基-3,5-二-三氟甲基-苯甲酰胺
将830mg N-[[4-[1-(2-氨基羰基-5-三氟甲基-苯基)]-哌啶基]-苄基氨基]-磺酰基-3,5-二-三氟甲基-苯甲酰胺溶解于20ml MeOH中并且在40℃下、在10%披钯炭存在的情况下将所得混合物氢化约12小时。滤除催化剂并将所得滤液经硅胶柱层析。得到N-[[4-[1-(2-氨基羰基-5-三氟甲基-苯基)]-哌啶基]-氨基]-磺酰基-3,5-二-三氟甲基-苯甲酰胺。mp 192-195℃。1H-NMR(DMSO)δ:1.58(m,2H),1.94(m,2H),2.77(m,2H),3.11-3.21(m,3H),5.8(宽峰,1H,NH),7.32(s,1H),7.36(d,1H),7.69(宽峰,1H),7.74(d,1H),8.16(s,1H),8.22(宽峰,1H),8.48(s,2H)。
根据类似于上述实施例1的方法,选用适当的原料得到式Iss化合物
其中R3ss和R4ss及其所构成化合物的熔点如表1所定义:
表1
实施例5
3,5-二(三氟甲基)苯甲酰基-氨基磺酸N-BOC-哌嗪酰胺
A)N-BOC-哌嗪-N′-氨基磺酸盐
将溶于20ml CH2Cl2中的612mg酰氨基磺酰氯加入1g BOC-哌嗪和1.085g三乙胺的溶液内。在0℃下所得混合物搅拌大约6小时并将温度温热至室温过夜。蒸发所得混合物的溶剂,将所得的蒸发残留物溶解于乙酸乙酯中,用水冲洗,干燥并浓缩。所得的浓缩残留物经硅胶柱层析。得到晶形的N-BOC-哌嗪-N′-氨基磺酸盐。m.p.:167-171℃。
B)3,5-二(三氟甲基)苯甲酰基-氨基磺酸N-BOC-哌嗪酰胺
将195mg N-BOC-哌嗪-N′-氨基磺酸盐和148mg三乙胺的溶液加入溶于50ml CH2Cl2的406mg 3,5-二(三氟甲基)苯甲酰氯内。在室温下将所得混合物搅拌大约20小时,去除溶剂,将所得的蒸发残留物溶解于EtAc中,用水冲洗,干燥并浓缩。所得浓缩残余物经硅胶柱层析。得到晶形的3,5-二(三氟甲基)苯甲酰基-氨基磺酸N-BOC-哌嗪酰胺。m.p.:185-190℃。
1H-NMR δ:1.4(s,9H,BOC),3.0-3.2(m,4H),3.3-3.5(m,4H),7.78(s,1H),8.28(s,2H).
根据类似于上述实施例5的方法,选用适当的原料得到式Is化合物
其中R3s和R4s及其所构成化合物的熔点如表2所示:
TABLE 2
Claims (9)
2.权利要求1的式I化合物,其中所述(C1-6)卤代烷基为CF3。
5.选自式Is化合物组的权利要求1化合物:
其中
a.R3s为3,5-二(三氟甲基)苯基,R4s为叔丁氧基羰基,
b.R3s为2,3-二氯苯基,R4s为叔丁氧基羰基,
c.R3s为3,5-二氯苯基,R4s为叔丁氧基羰基,
d.R3s为3,5-二(三氟甲基)苯基,R4s为苄氧基羰基,
e.R3s为2,3-二氯苯基,R4s为苄氧基羰基,
f.R3s为3,5-二氯苯基,R4s为苄氧基羰基,
g.R3s为3,5-二(三氟甲基)苯基,R4s为2-氨基羰基-5-三氟甲基苯基,
h.R3s为3,5-二氯苯基,R4s为2-氨基羰基-5-三氟甲基苯基,
i.R3s为2,3-二氯苯基,R4s为2-氨基羰基-5-三氟甲基苯基,以及
j.R3s为2-(3,5-二(三氟甲基)苯基)乙基,R4s为叔丁氧基羰基。
6.权利要求1、2、3和5中任一项的化合物,为盐形式。
7.权利要求1至6中任一项的化合物在制备用于治疗类固醇硫酸酯酶介导的紊乱的药物中的用途。
8.权利要求1至6中任一项的化合物在制备治疗类固醇硫酸酯酶介导的紊乱的药物中的用途。
9.药物组合物,该组合物包括权利要求1至6中任一项的化合物和至少一种药物赋形剂。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207500A GB0207500D0 (en) | 2002-03-28 | 2002-03-28 | Organic compounds |
GB0207500.0 | 2002-03-28 | ||
GB0225679.0 | 2002-11-04 | ||
GB0225679A GB0225679D0 (en) | 2002-11-04 | 2002-11-04 | Organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1646509A CN1646509A (zh) | 2005-07-27 |
CN1293065C true CN1293065C (zh) | 2007-01-03 |
Family
ID=28676499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038083361A Expired - Fee Related CN1293065C (zh) | 2002-03-28 | 2003-03-27 | 作为类固醇硫酸酯酶抑制剂的哌嗪基-或哌啶基胺─氨基磺酸酰胺 |
Country Status (20)
Country | Link |
---|---|
US (2) | US7439362B2 (zh) |
EP (1) | EP1492782A1 (zh) |
JP (1) | JP4580652B2 (zh) |
KR (1) | KR20040094877A (zh) |
CN (1) | CN1293065C (zh) |
AR (1) | AR039156A1 (zh) |
AU (1) | AU2003226732B2 (zh) |
BR (1) | BR0308795A (zh) |
CA (1) | CA2480686A1 (zh) |
CO (1) | CO5640113A2 (zh) |
IL (1) | IL164267A0 (zh) |
MX (1) | MXPA04009453A (zh) |
MY (1) | MY136880A (zh) |
NO (1) | NO20044321L (zh) |
NZ (1) | NZ535617A (zh) |
PE (1) | PE20040167A1 (zh) |
PL (1) | PL372602A1 (zh) |
RU (1) | RU2329258C2 (zh) |
TW (1) | TW200306806A (zh) |
WO (1) | WO2003082842A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0505541D0 (en) * | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
GB0505539D0 (en) * | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
GB0511190D0 (en) * | 2005-06-01 | 2005-07-06 | Sterix Ltd | Use |
KR20100068287A (ko) | 2007-09-17 | 2010-06-22 | 쁘레글렘 에스.아. | 폐경기 전 여성의 에스트로겐 의존성 질환의 치료 |
CN109069658B (zh) | 2016-02-08 | 2022-10-14 | 西纳福克斯股份有限公司 | 用于靶向her2肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法 |
EP3413920A1 (en) * | 2016-02-08 | 2018-12-19 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
WO2017137423A1 (en) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Improved sulfamide linkers for use in bioconjugates |
WO2018102419A1 (en) * | 2016-11-29 | 2018-06-07 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
CN114761383A (zh) * | 2019-06-12 | 2022-07-15 | 诺瑟拉有限公司 | 磺酰胺衍生物及其用途 |
CN110590896B (zh) * | 2019-11-04 | 2022-08-30 | 上海高准医药有限公司 | 雌酚酮硫酸酯哌嗪的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0089089A1 (en) * | 1982-03-12 | 1983-09-21 | Duphar International Research B.V | Phenyl piperazine derivatives having antiaggressive activity |
WO2001002349A1 (fr) * | 1999-07-06 | 2001-01-11 | Teikoku Hormone Mfg. Co., Ltd. | Derives phenyl-sulfamates |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US71516A (en) * | 1867-11-26 | William b | ||
US183459A (en) * | 1876-10-17 | Improvement in hinges | ||
US478328A (en) * | 1892-07-05 | Glass-heating oven | ||
US89089A (en) * | 1869-04-20 | Improved car-coupling | ||
US51547A (en) * | 1865-12-19 | Improvement in guide and tuck-marker for sewing-machines | ||
US876846A (en) * | 1907-05-28 | 1908-01-14 | Stephen W Smith | Road-machine. |
US1122242A (en) * | 1912-05-13 | 1914-12-29 | Sanitary Can Company | Can-body-feeding device. |
US2103610A (en) * | 1935-04-30 | 1937-12-28 | Sofal Ltd | Alloy steels |
DE876846C (de) * | 1943-06-01 | 1953-05-18 | Bayer Ag | Verfahren zur Herstellung von Abkoemmlingen des Sulfondiamids |
US3004487A (en) * | 1959-12-07 | 1961-10-17 | Bank Of America Nat Trust & Savings Ass | Imprinters |
GB1593609A (en) * | 1978-01-31 | 1981-07-22 | Christiaens Sa A | Pyridine sulfonamides |
FR2510106A1 (fr) | 1981-07-27 | 1983-01-28 | Rhone Poulenc Agrochimie | Composes herbicides derives d'acides phenoxybenzoiques, et leurs procedes de preparation et d'utilisation |
US5238923A (en) * | 1989-05-26 | 1993-08-24 | Warner-Lambert Company | Amino-substituted heterocycles as renin inhibitors |
US5256632A (en) * | 1990-05-30 | 1993-10-26 | Bayer Aktiengesellschaft | Herbicidal sulphonylated carboxamides |
IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
FR2716883B1 (fr) * | 1994-03-04 | 1996-04-26 | Roussel Uclaf | Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant. |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
WO1996002530A1 (en) | 1994-07-20 | 1996-02-01 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
JPH10510512A (ja) | 1994-10-04 | 1998-10-13 | 藤沢薬品工業株式会社 | 尿素誘導体とacat阻害剤としての用途 |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
DE19621483A1 (de) * | 1996-05-29 | 1997-12-04 | Hoechst Ag | Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19621482A1 (de) * | 1996-05-29 | 1997-12-04 | Hoechst Ag | Substituierte 1-Naphthoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
CA2285685A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
US6673799B1 (en) | 1998-09-22 | 2004-01-06 | Yamanouchi Pharmaceutical Co. Ltd. | Cyanophenyl derivative |
EP1165013A4 (en) | 1999-03-03 | 2002-08-07 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
JP2003500390A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Xa因子阻害剤 |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
PT1226127E (pt) | 2000-05-04 | 2009-07-23 | Basf Se | Fenilsulfamoílcarboxamidas substituídas com uracilo |
EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
ES2258642T3 (es) | 2001-07-02 | 2006-09-01 | Astrazeneca Ab | Derivados de piperidina utiles como moduladores de la actividad del receptor de quimiocina. |
-
2003
- 2003-03-26 AR ARP030101062A patent/AR039156A1/es unknown
- 2003-03-26 PE PE2003000308A patent/PE20040167A1/es not_active Application Discontinuation
- 2003-03-27 CA CA002480686A patent/CA2480686A1/en not_active Abandoned
- 2003-03-27 CN CNB038083361A patent/CN1293065C/zh not_active Expired - Fee Related
- 2003-03-27 PL PL03372602A patent/PL372602A1/xx unknown
- 2003-03-27 US US10/509,259 patent/US7439362B2/en not_active Expired - Fee Related
- 2003-03-27 JP JP2003580309A patent/JP4580652B2/ja not_active Expired - Fee Related
- 2003-03-27 EP EP03745281A patent/EP1492782A1/en not_active Withdrawn
- 2003-03-27 TW TW092106942A patent/TW200306806A/zh unknown
- 2003-03-27 NZ NZ535617A patent/NZ535617A/en unknown
- 2003-03-27 WO PCT/EP2003/003214 patent/WO2003082842A1/en active Application Filing
- 2003-03-27 BR BR0308795-6A patent/BR0308795A/pt not_active IP Right Cessation
- 2003-03-27 AU AU2003226732A patent/AU2003226732B2/en not_active Ceased
- 2003-03-27 IL IL16426703A patent/IL164267A0/xx unknown
- 2003-03-27 KR KR10-2004-7015312A patent/KR20040094877A/ko not_active Application Discontinuation
- 2003-03-27 RU RU2004131822/04A patent/RU2329258C2/ru not_active IP Right Cessation
- 2003-03-27 MX MXPA04009453A patent/MXPA04009453A/es active IP Right Grant
- 2003-03-28 MY MYPI20031151A patent/MY136880A/en unknown
-
2004
- 2004-09-28 CO CO04096497A patent/CO5640113A2/es unknown
- 2004-10-12 NO NO20044321A patent/NO20044321L/no not_active Application Discontinuation
-
2008
- 2008-09-16 US US12/211,525 patent/US20090042899A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0089089A1 (en) * | 1982-03-12 | 1983-09-21 | Duphar International Research B.V | Phenyl piperazine derivatives having antiaggressive activity |
WO2001002349A1 (fr) * | 1999-07-06 | 2001-01-11 | Teikoku Hormone Mfg. Co., Ltd. | Derives phenyl-sulfamates |
Also Published As
Publication number | Publication date |
---|---|
AU2003226732A1 (en) | 2003-10-13 |
US7439362B2 (en) | 2008-10-21 |
AR039156A1 (es) | 2005-02-09 |
JP4580652B2 (ja) | 2010-11-17 |
WO2003082842A1 (en) | 2003-10-09 |
RU2329258C2 (ru) | 2008-07-20 |
EP1492782A1 (en) | 2005-01-05 |
RU2004131822A (ru) | 2005-07-10 |
IL164267A0 (en) | 2005-12-18 |
CN1646509A (zh) | 2005-07-27 |
CO5640113A2 (es) | 2006-05-31 |
NO20044321L (no) | 2004-10-12 |
KR20040094877A (ko) | 2004-11-10 |
JP2005526812A (ja) | 2005-09-08 |
US20090042899A1 (en) | 2009-02-12 |
CA2480686A1 (en) | 2003-10-09 |
US20060052393A1 (en) | 2006-03-09 |
AU2003226732B2 (en) | 2006-12-21 |
PL372602A1 (en) | 2005-07-25 |
MXPA04009453A (es) | 2005-01-25 |
NZ535617A (en) | 2006-04-28 |
TW200306806A (en) | 2003-12-01 |
MY136880A (en) | 2008-11-28 |
PE20040167A1 (es) | 2004-05-26 |
BR0308795A (pt) | 2005-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1137125C (zh) | 稠合的1,2,4-噻二嗪衍生物、其制备方法和用途 | |
CN1206228C (zh) | 作为nos抑制剂的n-杂环衍生物 | |
CN1059436C (zh) | 苯并氮杂䓬-、苯并氧氮杂䓬-和苯并硫氮杂䓬-n-乙酸衍生物 | |
CN100347170C (zh) | 具有dpp-iv抑制活性的氮杂二环辛烷与壬烷衍生物 | |
EP1527048B1 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
CN1090188C (zh) | 新的苯并萘啶类化合物 | |
CN1726034A (zh) | 亚甲基桥连的选择性雄激素受体调节剂及其应用方法 | |
CN85107020A (zh) | 烷基亚磺酰胺基苯基烷基胺的制备方法 | |
CN1141043A (zh) | 非肽类速激肽受体拮抗剂 | |
CN1293065C (zh) | 作为类固醇硫酸酯酶抑制剂的哌嗪基-或哌啶基胺─氨基磺酸酰胺 | |
CN1309711C (zh) | 3-酰氨基-1,2-苯并异噁唑衍生物、其制备方法及应用 | |
CN1198096A (zh) | 用于治疗与胶原蛋白过量产生有关的疾病的c-蛋白酶抑制剂 | |
CN1148350C (zh) | 新型VLA-4抑制剂:oMePUPA-V | |
JP2015512913A (ja) | グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体 | |
CN1015707B (zh) | 酰胺衍生物的生产方法 | |
CN1636980A (zh) | 二肽腈组织蛋白酶k抑制剂 | |
CN1671387A (zh) | 芳基取代的乙内酰脲化合物及其作为钠通道阻滞剂的应用 | |
CN1325380A (zh) | 苯衍生物和它们的药物用途 | |
CN1036064C (zh) | 新的具有ngf生成促进活性的苯衍生物的制备方法 | |
CN1305465A (zh) | 芳基链烷酰基哒嗪化合物 | |
CN1340056A (zh) | 类固醇硫酸酯酶抑制剂以及它们的制备和应用方法 | |
CN1104017A (zh) | 取代的(芳烷氧基苄基)氨基丙酰胺衍生物及其制备方法 | |
CN1125575A (zh) | 粘附受体拮抗剂 | |
CN1101259A (zh) | 新型七叶亭衍生物及医药组合物 | |
CN1030921C (zh) | 制备δ4-甾类化合物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070103 Termination date: 20110327 |